Fiche publication
Date publication
mai 2016
Journal
British journal of clinical pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MERLIN Jean-Louis
Tous les auteurs :
Bernadou G, Campone M, Merlin JL, Gouilleux-Gruart V, Bachelot T, Lokiec F, Rezai K, Arnedos M, Diéras V, Jimenez M, Paintaud G, Ternant D
Lien Pubmed
Résumé
Trastuzumab, an antibody binding to epidermal growth factor receptor-2 (HER2), has been approved to treat HER2-positive breast cancer in different settings. This study aimed at evaluating the influence of tumour size on trastuzumab pharmacokinetics (PK) in non-metastatic breast cancer patients treated with short term pre-operative trastuzumab.
Mots clés
Adult, Aged, Antineoplastic Agents, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, administration & dosage, Breast Neoplasms, drug therapy, Everolimus, administration & dosage, Female, Half-Life, Humans, Middle Aged, Receptor, ErbB-2, metabolism, Trastuzumab, administration & dosage, Tumor Burden, Ultrasonography, Mammary
Référence
Br J Clin Pharmacol. 2016 May;81(5):941-8
